Alzheimer disease trials in Serbia
8 trials · From ClinicalTrials.gov, checked 10 Nov 2026. Ask the study team whether a trial fits you.
Phase 2/3RecruitingTrial-stage medicine
ACP-204 in Adults With Alzheimer's Disease Psychosis
- Where
- Belgrade, Gornja Toponica, Kovin, Kragujevac, Niš, Novi Kneževac, Sombor, Valjevo
- Age
- 55 years to 95 years
- People
- 1,074 worldwide
- Run by
- ACADIA Pharmaceuticals Inc.
See details and how to joinNCT06159673EU 2023-507325-42-00Registry updated 2026-11-05
Phase 3Enrolling by invitationTrial-stage medicine
ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study
- Where
- Belgrade, Gornja Toponica, Kovin, Kragujevac, Niš
- Age
- 55 years to 95 years
- People
- 752 worldwide
- Run by
- ACADIA Pharmaceuticals Inc.
See details and how to joinNCT06194799EU 2023-507351-29-00Registry updated 2026-11-04
Phase 2RecruitingTrial-stage medicine
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease
- Where
- Belgrade, Kovin, Kragujevac, Niš, Novi Kneževac
- Age
- 55 years and over
- People
- 370 worldwide
- Run by
- Intra-Cellular Therapies, Inc.
See details and how to joinNCT06540833Registry updated 2026-11-03
Phase 2RecruitingTrial-stage medicine
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia
- Where
- Belgrade, Kovin, Niš, Novi Kneževac
- Age
- 55 years and over
- People
- 320 worldwide
- Run by
- Intra-Cellular Therapies, Inc.
See details and how to joinNCT06651567EU 2024-514680-26-00Registry updated 2026-11-03
Phase 3RecruitingTrial-stage medicine
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
- Where
- Belgrade, Gornja Toponica, Kovin, Kragujevac, Novi Sad
- Age
- 55 years to 90 years
- People
- 406 worldwide
- Run by
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
See details and how to joinNCT06585787EU 2024-516363-92-00Registry updated 2026-10-27
Phase 3RecruitingTrial-stage medicine
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
- Where
- Belgrade, Gornja Toponica, Kovin, Kragujevac, Novi Sad, Vršac
- Age
- 55 years to 90 years
- People
- 1,000 worldwide
- Run by
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
See details and how to joinNCT05980949EU 2023-504151-27-00Registry updated 2026-10-16
Phase 2RecruitingTrial-stage medicine
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
- Where
- Kragujevac
- Age
- 55 years to 90 years
- People
- 300 worldwide
- Run by
- MapLight Therapeutics
See details and how to joinNCT06887192EU 2024-519820-26-00Registry updated 2026-09-30
Phase 3RecruitingTrial-stage medicine
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)
- Where
- Belgrade, Kovin, Kragujevac, Novi Sad, Vršac
- Age
- 55 years to 90 years
- People
- 410 worldwide
- Run by
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
See details and how to joinNCT05511363Registry updated 2026-08-17
All Alzheimer disease trials and the map
This page is not medical advice. Talk to your doctor before contacting a trial.